Cargando…
Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer
Despite extensive efforts, there has been limited progress in optimizing treatment of ovarian cancer patients. The vast majority of patients experience recurrence within a few years despite a high response rate to upfront therapy. The minimal improvement in overall survival of ovarian cancer patient...
Autores principales: | Roane, Brandon M., Arend, Rebecca C., Birrer, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562901/ https://www.ncbi.nlm.nih.gov/pubmed/31091744 http://dx.doi.org/10.3390/cancers11050668 |
Ejemplares similares
-
Prognostic Values of Transforming Growth Factor-Beta Subtypes in Ovarian Cancer
por: Zhou, Junhan, et al.
Publicado: (2020) -
Transforming Growth Factor-Beta (TGFβ) Signaling Pathway in Cholangiocarcinoma
por: Papoutsoglou, Panagiotis, et al.
Publicado: (2019) -
Targeting transforming growth factor beta signaling in metastatic osteosarcoma
por: Ge, Rongrong, et al.
Publicado: (2023) -
Transforming Growth Factor-Beta Signaling in Cancer-Induced Cachexia: From Molecular Pathways to the Clinics
por: Balsano, Rita, et al.
Publicado: (2022) -
Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment
por: Goldsberry, Whitney N., et al.
Publicado: (2020)